Catalog No.: PC-24036Not For Human Use, Lab Use Only.
TNG348 is a potent, a selective, allosteric and reversible USP1 inhibitor with IC50 of 98.6 nM in AlphaLISA-based measurement of ub-PCNA induction in MDA-MB-436 cells.
TNG348 is a potent, a selective, allosteric and reversible USP1 inhibitor with IC50 of 98.6 nM in AlphaLISA-based measurement of ub-PCNA induction in MDA-MB-436 cells.
TNG348 induces a dose-dependent loss of viability in the BRCA1-mutant MDA-MB-436 cell line with an average IC50 of 68.3 nM, while having no impact on the BRCA1 WT HCC1954 cell line.
TNG348 exhibits high selectivity in a panel of 47 DUBs (Ubiquigent), including USP12 and USP46, as well as against 467 of the 468 kinases tested.
TNG348 is active in BRCA mutant and HRD+ breast and ovarian cancer cells and acts through a distinct mechanism from PARPi.
TNG348 synergizes with PARPi and other DNA-damaging agents in HRD+ and BRCA-mutant cell lines.
TNG348 drives strong antitumor activity in combination with PARPi in HRD+ models and can overcome PARPi resistance.
